clinical trial · NCT06957431
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Advanced LeiomyosarcomaAdipocytic SarcomaAdvanced LiposarcomaZanzalintinibEribulin
brief summary
The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.
started
Oct 22, 2025
primary completion
Nov 30, 2028
completion
Oct 31, 2033
last updated
Oct 24, 2025
official title
A Phase I Trial of Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol